摘要
多黏菌素最早是从多黏芽孢杆菌培养液中发现的,并于上世纪50年代被应用于临床,但很快因为肾毒性等药物不良反应较大而被其他抗菌药物替代。然而,随着细菌耐药形势的日趋严峻,多黏菌素又重新回到临床,主要被用于产超广谱β内酰胺酶的革兰阴性菌甚至耐碳青霉烯的肠杆菌科细菌所致的严重感染。尽管多黏菌素被重新被用于临床,但其药物不良反应仍是需要被重点考量和监测的。为此,本文从发生机制、危险因素、应对策略等方面对多黏菌素的药物不良反应进行了综述,以期为多黏菌素的临床安全合理使用提供参考。
Polymyxin was first discovered in bacillus polymyxin culture medium and was applied in clinical practice in the 1950s.However,it was quickly replaced by other antibacterial drugs due to significant adverse reactions such as nephrotoxicity.Nevertheless,with the increasingly severe bacterial resistance,polymyxin has returned to clinical practice,and is mainly used for severe infections caused by extended-spectrum beta-lactamase-producing Gram-negative bacteria and even carbapenem-resistant Enterobacteriaceae.Although polymyxin has been re-used in clinical practice,its adverse drug reactions still need to be carefully considered and monitored.Therefore,this article reviews the adverse drug reactions of polymyxin from pathogenesis,risk factors and countermeasures,so as to provide reference for safe and reasonable use of polymyxin in clinical practice.
作者
张世杰
刘婧
ZHANG Shi-jie;LIU Jing(Ganzhou Municipal Hospital,Ganzhou Jiangxi 341000,China;Pharmacy Department of First Affiliated Hospital of Nanchang University,Nanchang 330000,China)
出处
《抗感染药学》
2023年第5期458-461,共4页
Anti-infection Pharmacy
作者简介
张世杰(1985-),男,主管药师;通信作者:刘婧(1991-),女,主管药师,电子邮箱:582935455@qq.com。
